NCT02280408View on ClinicalTrials.gov

Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 7, 2014

Primary Completion Date

December 10, 2015

Study Completion Date

December 10, 2015

Conditions
Ebola Viruses
Interventions
OTHER

Placebo

Normal saline placebo.

BIOLOGICAL

V920

Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

BioProtection Systems Corporation

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY